CHI3L2 and glioblastoma: And the data indicated that CD163 and CHI3L2 may serve as prognostic biomarkers in GBM and GBM patients with a high expression of CD163 and CHI3L2 which predicted a poor overall survival, prognosis-free survival, and disease-specific survival.